Ltt Bio-pharma Co., Ltd. (4566) - Financial And Strategic Analysis Review

Theravance, Inc

Theravance, Inc. (THRX) - Financial and Strategic Analysis Review

Theravance, Inc. (Theravance) is engaged in the discovery, development and commercialization of new medicines. Its drug discovery efforts are based on its expertise in multivalency. Multivalency involves the instantaneous attachment of a single molecule to multiple binding sites on biological targets. It also effectively partnered with leading global pharmaceutical and Astellas Pcompanies such as GlaxoSmithKline harma to accelerate the development and commercialization of product candidates. The company makes substantial investments in multivalency and other technologies to maintain its competitive advantages in the area of drug discovery.

Theravance, Inc. Key Recent Developments

Apr 15, 2010: Theravance Begins Proof of Concept TD-1211 Phase 2 Trial

Nov 30, 2009: FDA Provides Complete Response Letter To Theravance For Telavancin

Nov 30, 2009: EMEA Completes Validation Phase For Theravance's Telavancin MAA

Nov 05, 2009: Theravance, Astellas Launch Vibativ In US

This comprehensive SWOT profile of Theravance, Inc. provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of the Profile on Demand service, covering over 50,000 of the worlds leading companies. Once purchased, the highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Theravance, Inc., including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days (excluding weekends).

The profile contains critical company information including*,

- Business description A detailed description of the companys operations and business divisions.

- Corporate strategy Analysts summarization of the companys business strategy.

- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.

- Company history Progression of key events associated with the company.

- Major products and services A list of major products, services and brands of the company.

- Key competitors A list of key competitors to the company.

- Key employees A list of the key executives of the company.

- Executive biographies A brief summary of the executives employment history.

- Key operational heads A list of personnel heading key departments/functions.

- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

For more information, please visit:

http://www.aarkstore.com/reports/Theravance-Inc-THRX-Financial-and-Strategic-Analysis-Review-47508.html

Aarkstore Enterprise

Name: Jessica

Email: Jessica@aarkstore.com

Url: http://www.aarkstore.com/

Contact:08149852585

by: Aarkstore Enterprise

Ltt Bio-pharma Co., Ltd. (4566) - Financial And Strategic Analysis Review

Theravance, Inc

Contact

www.yloan.com

Products

Our Solutions

Press Room

Resources